AstraZeneca CEO: AI is affecting every part of our company

AstraZeneca CEO Pascal Soriot joins CNBC’s Angelica Peebles to discuss the most promising drugs in AstraZeneca’s pipeline. He says the future is about innovating into new indications with the drugs and technologies they already have in house. He says in the last 3 years the company has averaged one positive trial result readout every month. As far as dabbling in AI, the company created a specialized AI unit to help accelerate research and discovery.